Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Colorcon
Cantor Fitzgerald
Argus Health
Merck
Citi
UBS
Federal Trade Commission
Chinese Patent Office

Generated: June 25, 2018

DrugPatentWatch Database Preview

ELLA Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Ella patents expire, and what generic alternatives are available?

Ella is a drug marketed by Lab Hra Pharma and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-three patent family members in twenty-seven countries.

The generic ingredient in ELLA is ulipristal acetate. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ulipristal acetate profile page.
Drug patent expirations by year for ELLA
Pharmacology for ELLA
Synonyms for ELLA
(10S,11S,14R,15S,17R)-14-acetyl-17-[4-(dimethylamino)phenyl]-15-methyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1,6-dien-14-yl acetate
(10S,11S,14R,15S,17R)-14-acetyl-17-[4-(dimethylamino)phenyl]-15-methyl-5-oxotetracyclo[8.7.0.0?,?.0??,??]heptadeca-1,6-dien-14-yl acetate
(10S,11S,14R,15S,17R)-14-ACETYL-17-[4-(DIMETHYLAMINO)PHENYL]-15-METHYL-5-OXOTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADECA-1,6-DIEN-14-YL ACETATE
(11beta,17alpha)-17-acetyl-11-[4-(dimethylamino)phenyl]-3-oxoestra-4,9-dien-17-yl acetate
(11beta)-17-(Acetyloxy)-11-(4-(dimethylamino)phenyl)-19-norpregna-4,9-diene-3,20-dione
(11beta)-17-(Acetyloxy)-11-[4-(dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione
(8S,11R,13S,14S,17R)-17-acetyl-11-(4-(dimethylamino)phenyl)-13-methyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate
[(8S,11R,13S,14S,17R)-17-acetyl-11-(4-dimethylaminophenyl)-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate
126784-99-4
17-Acetoxy-11-(4-N,N-dimethylaminophenyl)pregna-4,9-diene-3,20-dione
17beta-acetyl-11beta-[4-(dimethylamino)phenyl]-3-oxoestra-4,9-dien-17alpha-yl acetate
19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-(4-(dimethylamino)phenyl)-, (11beta)-
19-Norpregna-4,9-diene-3,20-dione,17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11b)-
3B1-000818
4oar
5-(Hydroxymethyl)-alpha,alpha,alpha,alpha-tetramethyl-1,3-benzenediacetonitrile
784A994
AB01566874_01
AC1L2Y8A
AKOS026750526
AMX10180
BDBM50375424
C30H37NO4
CBD 2914; VA 2914; (11b)-17-(Acetyloxy)-11-[4-(dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione
CDB 2914
CDB-2914
CHEBI:71025
CHEMBL260538
CS-1157
D09687
DTXSID30155294
EllaOne
EllaOne|||Esmya
EN300-220766
Esmya
FT-0675731
GTPL7460
Hrp-2000
HY-16508
J-005436
KB-81383
KS-00000Z24
MolPort-006-170-077
OOLLAFOLCSJHRE-ZHAKMVSLSA-N
PL009540
RTI 3021-012
SC-44720
SCHEMBL544957
U0102
Ulipristal (acetate)
Ulipristal acet
Ulipristal acetate
Ulipristal acetate (JAN/USAN)
Ulipristal acetate [USAN]
Ulipristal acetate, >=98% (HPLC)
Ulipristal acetate(CDB2914)
Ulipristal-Acetate
UNII-YF7V70N02B
VA2914
W-5201
X4788
YF7V70N02B
Z2216208644
ZINC3920657

US Patents and Regulatory Information for ELLA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lab Hra Pharma ELLA ulipristal acetate TABLET;ORAL 022474-001 Aug 13, 2010 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Lab Hra Pharma ELLA ulipristal acetate TABLET;ORAL 022474-001 Aug 13, 2010 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Lab Hra Pharma ELLA ulipristal acetate TABLET;ORAL 022474-001 Aug 13, 2010 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Lab Hra Pharma ELLA ulipristal acetate TABLET;ORAL 022474-001 Aug 13, 2010 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for ELLA
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 30 mg ➤ Subscribe 2014-08-13

Non-Orange Book US Patents for ELLA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,844,510 Ulipristal acetate tablets ➤ Sign Up
9,616,073 Method for on-demand contraception ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Argus Health
Merck
Fuji
Teva
Chubb
McKesson
Citi
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.